Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4507-4512

  Hoogwater, Frederik J H ^a   Snoeren, Nikol ^a   Nijkamp, Maarten W ^a   Gunning, Amy C ^a   Van Houdt, Winan J ^a   De Bruijn, Menno T ^a   Voest, Emile E ^a   Van Hillegersberg, Richard ^a   Kranenburg, Onno ^a   Borel Rinkes, Inne H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biomarker; CD95 ligand; Colorectal cancer; Liver metastases; Surgery

Indexed keywords

FAS LIGAND;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER SURGERY; COLORECTAL CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEMORIAL SLOAN KETTERING CANCER CENTRE CLINICAL RISK SCORE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855161183     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Khatri VP, Petrelli NJ and Belghiti J: Extending the frontiers of surgical therapy for hepatic colorectal metastases: Is there a limit? J Clin Oncol 23: 8490-8499, 2005.
2. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS and Lee PH: Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14: 786-794, 2007.
3. Martin RC, Augenstein V, Reuter NP, Scoggins CR and McMasters KM: Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg 208: 842-850, 2009.
4. Dhein J, Walczak H, Baumler C, Debatin KM and Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441, 1995.
5. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, Raats DA, Sprick MR, Schaefer U, van Houdt WJ, de Bruijn MT, Schackmann RC, Derksen PW, Medema JP, Walczak H, Borel Rinkes IH and Kranenburg O: Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 138: 2357-2367, 2010.
6. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, TschoppJ, Wajant H, Wallach D, Wiltrout RH, Zörnig M and Lynch DH: The CD95 receptor: apoptosis revisited. Cell 129: 447-450, 2007. (Pubitemid 46660984)
7. Bennett MW, O'Connell J, Houston A, Kelly J, O'Sullivan GC, Collins JK and Shanahan F: Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol 54: 598-604, 2001. (Pubitemid 32756440)
8. Mann B, Gratchev A, Böhm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ and Hanski C: FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79: 1262-1269, 1999. (Pubitemid 29087908)
9. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH and Nagata S: Fas ligand in human serum. Nat Med 2: 317-322, 1996. (Pubitemid 26080652)
10. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Hynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L and Strasser A: Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461: 659-663, 2009.
11. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318, 1999.
12. Nijkamp MW, van der Bilt JD, Snoeren N, Hoogwater FJ, van Houdt WJ, Molenaar IQ, Kranenburg O, van Hillegersberg R and Borel Rinkes IH: Prolonged portal triad clamping during liver surgery for colorectal liver metastases is associated with decreased time to hepatic tumour recurrence. Eur J Surg Oncol 36: 182-188, 2010.
13. Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J and Van Custsem E: Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer - an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 8: 1579-84, 2010.
14. van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN and Verhoef C: Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg 97: 383-390, 2010.
15. Capussotti L, Vigano' L, Ferrero A, Lo TR, Ribero D and Polastri R: Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 14: 1143-1150, 2007.
16. Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, Kulisch E and Saeger HD: Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29: 89-102, 2009.
17. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ and Strarzl TE: Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189: 291-299, 1999. (Pubitemid 29408866)
18. Mann CD, Metcalfe MS, Leopardi LN and Maddern GJ: The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 139: 1168-1172, 2004. (Pubitemid 39463447)
19. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie: Cancer 77: 1254-1262, 1996. (Pubitemid 26102322)
20. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM and Nagomey DM: Hepatic resection for colorectal metastases: Value for risk scoring systems? Ann Surg 246(2): 183-91, 2007. (Pubitemid 47196514)
21. Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, Müller SA, Schemmer P, Büchler MW and Weitz J: Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 16(12): 3279-88, 2009.
22. Snoeren N, Voest E and van Hillegersberg R: Surgery vs. surgery and chemotherapy for colorectal liver metastases. Lancet 372(9634): 202-3, 2008. (Pubitemid 351978099)
23. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M and Kahan JP: OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23: 7125-7134, 2005.
24. Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O and Miki T: Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92: 287-293, 2001. (Pubitemid 32664434)
25. Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E and Asao T: Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 89: 2560-2564, 2000. (Pubitemid 32011599)
26. Kozlowski M, Kowalczuk O, Sulewska A, Dziegielewski P, Lapuc G, Laudanski W, Niklinska W, Chyczewski L, Niklinski J and Ludanski J: Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochem Cytobiol 45: 199-204, 2007. (Pubitemid 350018135)
27. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumra K and Ygita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777-1783, 1995.